TajikistanTuberculosis profile
Population  2017 8.9 million
Estimates of TB burden*, 2017 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.46 (0.35–0.6) 5.2 (3.9–6.7)
Mortality (HIV+TB only) 0.064 (0.047–0.084) 0.72 (0.53–0.94)
Incidence  (includes HIV+TB) 7.5 (5.8–9.5) 85 (65–106)
Incidence (HIV+TB only) 0.28 (0.18–0.4) 3.1 (2–4.5)
Incidence (MDR/RR-TB)** 2.3 (1.6–3.1) 26 (18–35)
Estimated TB incidence by age and sex (thousands)*, 2017
  0-14 years > 14 years Total
Females 0.4 (0.37–0.42) 3 (2.6–3.5) 3.4 (2.9–4)
Males 0.44 (0.41–0.46) 3.7 (3–4.3) 4.1 (3.4–4.8)
Total 0.83 (0.77–0.9) 6.7 (5.2–8.3) 7.5 (5.8–9.5)
TB case notifications, 2017  
Total cases notified 6 279
Total new and relapse 5 895
          - % tested with rapid diagnostics at time of diagnosis 52%
          - % with known HIV status 95%
          - % pulmonary 70%
          - % bacteriologically confirmed among pulmonary 68%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2017 78% (62–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2017 0.07 (0.05–0.1)
TB/HIV care in new and relapse TB patients, 2017 Number (%)
Patients with known HIV-status who are HIV-positive 219 4%
          - on antiretroviral therapy 117 53%
Drug-resistant TB care, 2017 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  940
(870–1 000)
Estimated % of TB cases with MDR/RR-TB 20% (19–22) 23% (20–27)  
% notified tested for rifampicin resistance 46% 62% 3 084
MDR/RR-TB cases tested for resistance to second-line drugs   515
Laboratory-confirmed cases MDR/RR-TB: 936, XDR-TB: 279
Patients started on treatment **** MDR/RR-TB: 570, XDR-TB: 250
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2016 89% 5 324
Previously treated cases, excluding relapse, registered in 2016 81% 212
HIV-positive TB cases registered in 2016 69% 147
MDR/RR-TB cases started on second-line treatment in 2015 58% 682
XDR-TB cases started on second-line treatment in 2015    
TB preventive treatment, 2017  
% of HIV-positive people (newly enrolled in care) on preventive treatment 47%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
96% (89–100)
TB financing, 2018  
National TB budget (US$ millions) 16
Funding source: 19% domestic, 62% international, 20% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2017
age_sex_graph
____
 
FemalesMalesIncidence

Treatment success rate (%)
tx success graph
   New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__
Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2018-09-26 Data: www.who.int/tb/data